Aurinia Pharmaceuticals Inc. (AUPH)
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $283.1M
- Net income
- $287.2M
- Total assets
- $751.6M
- Market cap
- $2.0B
- Gross margin
- 88.5%
- Operating margin
- 37.1%
- Net margin
- 101.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $283.1M
- Cost of revenue
- $32.7M
- Gross profit
- $250.4M
- Operating expenses
- $178.1M
- Operating income
- $104.9M
- Income tax
- -$173.0M
- Net income
- $287.2M
- EPS (basic)
- $2.14
- EPS (diluted)
- $2.07
Balance sheet
- Total assets
- $751.6M
- Current assets
- $492.0M
- Total liabilities
- $170.3M
- Current liabilities
- $93.7M
- Shareholders’ equity
- $581.3M
Cash flow
- Operating cash flow
- $135.7M
- Investing cash flow
- -$32.8M
- Financing cash flow
- -$106.1M
- Net cash flow
- -$3.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.0B
- P/E ratio
- 7.4
- EPS (diluted)
- $2.07
- Shares outstanding
- 132.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 21, 2009
Aurinia Pharmaceuticals Inc. (AUPH) Stock Price
- Profitable — net income of $287.2M in FY2025.
- Revenue grew 465% from FY2020 to FY2025.
- Gross margin of 88.5%, net margin 101.5%.
- Trading 18% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 7.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aurinia Pharmaceuticals Inc..
Write a review
News about Aurinia Pharmaceuticals Inc.
News & sentiment via Polygon.io
Aurinia Pharmaceuticals Inc.: frequently asked questions
Is Aurinia Pharmaceuticals Inc. an American company?
Aurinia Pharmaceuticals Inc. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Aurinia Pharmaceuticals Inc. publicly traded?
Yes — Aurinia Pharmaceuticals Inc. is a publicly traded company. Its stock trades under the ticker symbol AUPH on the NASDAQ.
What does Aurinia Pharmaceuticals Inc. do?
Aurinia Pharmaceuticals Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
